Systematic Elucidation and Validation of OncoProtein-Centric Molecular Interaction Maps
The largely incomplete and tissue-independent nature of cancer pathways represents a key limitation to the ability to elucidate mechanistic determinants of cancer phenotypes and to predict adaptive response to targeted therapy. To address these challenges, we propose replacing canonical cancer pathways with a more accurate, comprehensive, and context-specific architecture - dubbed a Protein-Centric molecular interaction Map (PC-Map) - representing modulators, effectors, and cognate binding-partners of any oncoprotein of interest. To reconstruct these complex molecular architectures de novo, we introduce a novel OncoSig algorithm. Validation of a lung adenocarcinoma specific (LUAD) KRAS-centric PC-Map recapitulated known KRAS biology and, more critically, identified a novel repertoire of proteins eliciting synthetic lethality in KRASG12D LUAD organoid cultures. Showing the generalizable nature of the algorithm, we elucidated PC-Maps for ten recurrently mutated oncoproteins, including KRAS, in distinct tumor contexts. This revealed a highly context-specific nature of cancers regulatory and signaling architectures to an unprecedented degree of resolution.